Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study
Open Access
- 31 May 2026
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (8) , 829-838
Abstract
Background: Comparative studies in paediatric-onset multiple sclerosis (PoMS) that also include highly effective monoclonal antibody therapies are rare. Objective: To compare treatment persistence, as a proxy of effectiveness and tolerability, across disease-modifying therapies (DMTs). Methods: Nationwide cohort study using Swedish MS Registry data on individuals with MS onset before age 18 from 2000 to 2024. Treatment persistence was analysed using Kaplan–Meier and Cox models, adjusted for demographics and treatment epoch. Results: We included 383 individuals (69.2% female; median onset age 15.8 and 17.2 years at first DMT start), observed for a median 10.1 years (interquartile range (IQR): 5.5–15.5), yielding 934 treatment episodes: rituximab (272), injectables (263), natalizumab (248), fingolimod (86) and dimethyl fumarate (65). Median age at any treatment initiation, regardless of treatment sequence, was 18.9 years, with a median Expanded Disability Status Scale (EDSS) score of 1.5 (IQR: 0.0–2.0). Treatment persistence never dropped below 50% for rituximab, while median persistence was 35.6 months for natalizumab (95% confidence interval (CI): 28.8–44.9), 34.7 for dimethyl fumarate (95% CI: 21.7–56.9), 32.0 for fingolimod (95% CI: 21.1–48.1) and 17.6 for injectables (95% CI: 14.4–20.8). Compared to injectables, adjusted hazard ratios (HRs) for discontinuation were significantly lower for rituximab (0.09; 95% CI: 0.07–0.12), natalizumab (0.39; 95% CI: 0.31–0.48), fingolimod (0.41; 95% CI: 0.30–0.55) and dimethyl fumarate (0.49; 95% CI: 0.36–0.68). Conclusion: Rituximab displayed the highest treatment persistence, supporting B-cell depletion as a first-line option in PoMS.Keywords
Funding Information
- The Swedish Brain Fund
- Sällskapet Barnavård
- Erling-Perssons Stiftelse
- Svenska Forskningsrådet Formas
- Bjarne Ahlström’s Memorial Fund
- Region Stockholm
- Kronprinsessan Lovisas förening för barnasjukvård och Stiftelsen Axel Tielmans Minnesfond
- Stiftelsen Samariten
This publication has 30 references indexed in Scilit:
- Completeness and generalizability of the Swedish MS registerEuropean Journal of Epidemiology, 2025
- Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimodJournal of Neurology, 2024
- COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with RituximabAnnals of Neurology, 2024
- Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With NatalizumabJAMA Network Open, 2024
- Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and TolerabilityDrugs, 2024
- Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple SclerosisJAMA Neurology, 2024
- Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple SclerosisAnnals of Neurology, 2020
- Fingolimod Rebound: A Review of the Clinical Experience and Management ConsiderationsNeurology and Therapy, 2019
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple SclerosisJAMA Neurology, 2018
- B‐cell Therapy for Multiple Sclerosis: Entering an eraAnnals of Neurology, 2017